Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Moduli of Crystals and K3 Surfaces (K3CRYSTAL)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Mathematics
Panel description: All areas of mathematics, pure and applied, plus mathematical foundations of computer science, mathematical physics and statistics
Countries involved: Germany
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-10-01
End date: 2021-09-30
Duration (months): 60.0
Total project cost (EUR): 1328710.0
EU funding (EUR): 1328710.0
Participants: 1
Project status: CLOSED

Algebraic geometry deals with algebraic varieties, that is, systems of polynomial equations and their geometric interpretation. Its ultimate goal is the classification of all algebraic varieties. For a detailed understanding, one has to construct their moduli spaces, and eventually study them over the integers, that is, in the arithmetic situation. So far, the best results are available for curves and Abelian varieties. To go beyond the aforementioned classes, I want to study arithmetic moduli spaces of the only other classes that are currently within reach, namely, K3 surfaces, Enriques surfaces, and Hyperkähler varieties. I expect this study to lead to finer invariants, to new stratifications of moduli spaces, and to open new research areas in arithmetic algebraic geometry. Next, I propose a systematic study of supersingular varieties, which are the most mysterious class of varieties in positive characteristic. Again, a good theory is available only for Abelian varieties, but recently, I established a general framework via deformations controlled by formal group laws. I expect to extend this also to constructions in complex geometry, such as twistor space, which would link so far completely unrelated fields of research. I want to accompany these projects by developing a general theory of period maps and period domains for F-crystals, with an emphasis on the supersingular ones to start with. This will be the framework for Torelli theorems that translate the geometry and moduli of K3 surfaces, Enriques surfaces, and Hyperkähler varieties into explicit linear algebra problems, thereby establishing new tools in algebraic geometry.

Keywords: k3 surfaces,moduli spaces,crystalline cohomology
Surface-grafted metallofullerene molecular magnets with controllable alignment of magnetic moments (GraM3)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physical and analytical chemical sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Germany
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-06-01
End date: 2020-11-30
Duration (months): 66.0
Total project cost (EUR): 1912181.0
EU funding (EUR): 1912181.0
Participants: 1
Project status: CLOSED

The molecules retaining their magnetization in the absence of magnetic field are known as single molecule magnets (SMMs). Important problems to be solved on the way to the applications of SMMs in molecular spintronics is their deposition on surfaces and addressing their spins on the single molecular level. In this project we will address these problems by designing SMMs based on endohedral metallofullerenes (EMFs) derivatized with anchoring groups. SMM behaviour recently discovered for DySc2N@C80 and Dy2ScN@C80 in PI’s group is governed by a strong magnetic anisotropy (magnetic moments of Dy ions are aligned along the Dy–N bonds) and ferromagnetic exchange interactions between Dy ions within the clusters. Protected by the carbon cages, these SMMs exhibit uniquely long zero-field relaxation times of several hours at 2 K and provide an ideal system for addressing the individual spin states. Spatial orientation of magnetic moments in EMF-SMMs is determined by the endohedral cluster and is therefore influenced by the orientation of the EMFs molecules and their internal dynamics. We will apply three strategies to control the spatial arrangement of the magnetic moments in EMF-SMMs: (i) deposition of EMF molecules via sublimation; (ii) exohedral modification of EMFs with anchoring groups for grafting of EMFs on surfaces; (iii) introducing photoswitchable units into the anchoring groups which can reversibly change their geometry upon impact of light and will allow switching direction of the magnetic moment in a fully controllable way. Magnetic behaviour of the surface-grafted SMMs will be studied by bulk- and surface-sensitive techniques including X-ray magnetic circular dichroism and especially spin-polarized scanning tunneling microscopy. Successful fulfillment of the objectives of this interdisciplinary high-risk/high-gain project will revolutionize the field of the surface molecular magnetism by allowing the study and control of the SMMs on a single spin level.

Keywords: single molecule magnetism,endohedral fullerene,self assembled monolayer,lanthanide
Cloud Protection: Centralized encryption technology for file sharing (CLAPPRO)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-2-2014, 2014)
Start date: 2015-07-01
End date: 2017-06-30
Duration (months): 24.0
Total project cost (EUR): 871615.0
EU funding (EUR): 610130.5
Participants: 1
Project status: CLOSED

The goal of CLAPPRO project is to create a world-class security standard for file sharing and file management in the cloud based on Data-Centric encryption, centralized access rights control and cross-platform accessibility. Protección Online SL (from now on, Prot-On) has devised for this project the development of a prototype of the complete version of their product, Prot-On SaaS. The solution is an Information Rights Management (IRM) Software-as-a-Service that aims at becoming the first cross-platform software that acts as a centralized protection layer for file encryption and permissions management and usage auditing. As a result, the solution ensures the protection of the information even when the file has been shared in a Cloud Storage service or downloaded in a local computer. More than 35 corporations are already using the prototype of the product, which is generating annual revenues of over € 200k. The company has already developed the core technology, a strong Data-Centric encryption module with access right management. The testing conducted on this technology, both by Large Companies and SMEs, have concluded that this solution is potentially fit for a mass and global market implantation, aiming at the B2C channels. However, while the current local expansion of the Company and the backing by VCs have sustained the development of Prot-On quite successfully, the scaling-up to the B2C, in order to establish a world-class security standard for Cloud sharing, requires additional development of features focused on usability, such multi-Cloud aggregation and UX interfaces, and funding for achieving a global reach and the optimal go-to-market speed.

Keywords: demonstration,final version,internationalization,piloting,b2c mass market entrance
Smart and intuitive osseointegrated transfemoral prostheses embodying advanced dynamic behaviors (MyLeg)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Partnership: Robotics SPARC (cPPP)
Countries involved: Italy,Australia,Iceland,Netherlands,Netherlands,Netherlands
Call: Advanced robot capabilities research and take-up (H2020-ICT-2017-1, 2017)
Start date: 2018-01-01
End date: 2023-02-28
Duration (months): 62.0
Total project cost (EUR): 4508750.0
EU funding (EUR): 3982250.0
Participants: 9
Project status: SIGNED

Limb loss is one of the most physically and psychologically devastating events that can happen to a person. In USA, the main causes of lower-limb amputation are vascular diseases (70%), trauma (22%), congenital or birth defects (4%), and tumors (4%). Even if with appropriate rehabilitation many people can learn to walk or function again, amputation continues to be a large problem, as there still remains a significant gap between the most advanced prosthetic devices and their anatomical counterparts. The MyLeg project aims at developing both a solid theoretical understanding and the enabling technologies for the realization of a new generation of transfemoral prostheses that can be intuitively operated, sensed, and trusted as the healthy counterpart. MyLeg introduces the concept of smart and intuitive osseointegrated transfemoral prostheses that embody advanced dynamic behaviors. The MyLeg prosthetic system will be directly anchored to the amputee’s bone by means of osseointegrated implant to enhance the human-prosthesis interaction, perception, and motion capabilities; it will include implantable myoelectric sensors on targeted reinnervated muscles to realize an intuitive EMG control and to provide a high-level of cognition abilities; it will implement variable stiffness actuators realized with stress-stiffening nanostructured materials that guarantee high adaptability with respect to different tasks, dependability, and decisional autonomy; it will exploit light-weighted nanofibrous materials for sensing and energy harvesting. As the MyLeg project aims for direct exploitation in the prosthetic market, the MyLeg prosthetic system will be evaluated with osseointegrated amputees in a wide variety of activities of daily living, with a clear focus on increased Technology Readiness Levels. The accomplishment of the envisaged scenarios will boost the European prosthetic sector, contribute to the goal of retaining Europe’s competitiveness, and impact the healthcare and th

Keywords: prostheses
Science Uncovered (Science Uncovered)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European researchers' Night
Action type: Marie Skłodowska-Curie actions
Countries involved: United Kingdom
Call: European Researchers' Night (H2020-MSCA-NIGHT-2016, 2016)
Start date: 2016-05-01
End date: 2017-12-31
Duration (months): 20.0
Total project cost (EUR): 528452.5
EU funding (EUR): 350591.0
Participants: 1
Project status: CLOSED

NHM has successfully delivered 11 events at 6 consecutive European Researchers’ Nights that have attracted increasing public participation and proactive engagement. SCIENCE UNCOVERED aims to build on this experience to deliver at least 10 captivating events in 5 locations across the UK in 2016 and 2017. Central objectives of SCIENCE UNCOVERED are to: [1] Actively breakdown existing public stereotypes of researchers [2] Create greater public awareness of the role of researchers and the value of science [3] Inspire the next generation of young researchers and demonstrate the varied roles and opportunities that are open to them for careers within science. An enhanced awareness campaign will make 34 million people aware of the ERN over two years. Awareness raising and a compelling array of activities will engage 20,500 participants directly. SCIENCE UNCOVERED aims to deliver deep public engagement with research as well as a greater dialogue between researchers and the wider public to further increase awareness of science and how future science benefits both European and global society. NHM strives to increase the public understanding of and engagement with science using extensive programme of high quality, innovative activities including media, capitalising on past experience and mobilising our network of providers in public engagement and research communities. NHM will be working with subcontractors to realise activities in 5 UK locations: London, Tring, Manchester, Newcastle and Belfast. The regional activities present an exceptional opportunity to reach “under-served” audiences including thousands of young people with limited opportunities to engage with research. SCIENCE UNCOVERED will deliver a high researcher-to-participant ratio of ca. 1:40 at all events as impact assessment demonstrates personalised interactions are particularly important to dispelling stereotypes and maximise the impact of this programme.

Keywords: science uncovered aims to,actively breakdown existing public stereotypes of researchers
Imaging life from Molecules to cells - building knowledge on Cryo-electron microscopy methodologies (IMpaCT)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Israel,Spain,Finland,Portugal
Call: Twinning (H2020-WIDESPREAD-2018-03, 2018)
Start date: 2019-09-01
End date: 2023-02-28
Duration (months): 42.0
Total project cost (EUR): 800000.0
EU funding (EUR): 800000.0
Participants: 4
Project status: CLOSED

Proteins are building blocks of life, often forming complexes with essential cellular roles. Dysfunction of proteins or their complexes in cells are associated with a wide variety of pathologies, making them excellent drug target candidates. Their 3D structures are essential for a rational drug design. However, many important proteins and complexes are extremely hard to crystallize. Recent advances in Cryo-Electron Microscopy methodologies enabled the structure determination of large macromolecular complexes at near-atomic resolution. An unprecedented level of detail in cell imaging using Cryo-Electron Tomography is also now possible. IMpaCT will improve the expertise at the UNL in Cryo-EM methodologies applied to the structural studies of proteins related to human health (e.g. cancer, antiviral infections) from individual molecules to macromolecular complexes, both isolated and in a cellular context. To this end, UNL will team up with renowned Cryo-EM experts from the National Centre for Biotechnology of the Spanish National Research Council (Spain), the Institute of Biotechnology of the University of Helsinki (Finland) and the Weizmann Institute of Science (Israel). A solid work programme grounded on hands-on Workshops will be complemented with short-term visits to the partner labs, visits from partner labs experts to ITQB NOVA, seminars by leading experts in Cryo-EM (e.g. Nobel Prize winners), industry stakeholders’ engagement via a Mini-symposium and workshop participation, knowledge transfer to other research groups in Portugal and a WP devoted to early-stage researchers. An ambitious Dissemination, Exploitation and Communication plan will be implemented to leverage the research results potentiated by this project as high-impact publications and invited communications at international meetings, leading to a fundamental outcome: an increased visibility and activity of UNL researchers as players in the Cryo-EM field.

Keywords: cancer,tuberculosis,cryo em microscopy,cryo em tomography,bacteria,human proteins
Zinc finger gene therapy in the brain for treating Huntington's disease (Fingers4Cure)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: United Kingdom
Call: ERC Proof of Concept Grant (ERC-2014-PoC, 2014)
Start date: 2015-02-01
End date: 2016-07-31
Duration (months): 18.0
Total project cost (EUR): 149995.0
EU funding (EUR): 149995.0
Participants: 1
Project status: CLOSED

Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years of age, although they can start much earlier. Suffering is high for both patients and carers, with death generally occurring within 10 - 15 years of diagnosis. We are working on a novel, curative gene therapy approach based on reducing the levels of the HTT disease gene products, while maintaining the levels of the normal protein. It is based on the delivery of proprietary zinc finger proteins (ZFPs) to the brain. Efficient delivery is accomplished through the use of viral vectors that carry the sequences coding for our ZFPs. Such ZFPs are artificially engineered proteins that specifically bind the defective expanded HTT DNA sequences (but not the normal HTT sequences or other, unrelated sequences). Binding represses the synthesis of the toxic gene products. We have published data demonstrating efficient mutant HTT repression in mouse (Garriga-Canut, M., et al. & Isalan M. Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145, 2012). We now need to improve the viral vectors for the long term expression of our ZFPs in the mouse brain, as the basis for a single-intervention, long-term therapy in humans (technical improvements). In parallel, we need to maintain the patent applications that protect the technology through various national and regional phases, and protect new developments that may arise (intellectual property), while engaging the necessary IPR and market studies/activities that help us find an industry partner that licenses our technology and moves it forward into the clinic (exploitation). This proof of concept grant is critical in all three aspects.

Keywords: zinc fingers,protein engineering,gene therapy
Industrial Production of Stable Fibroblast Growth Factors for Broad Therapeutic, Research, and Personal Care Applications (FGFSTAB)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Biotechnology
Action type: SME instrument
Countries involved: Czechia
Call: SME boosting biotechnology-based industrial processes driving competitiveness and sustainability (H2020-SMEINST-1-2014, 2014)
Start date: 2015-05-01
End date: 2015-10-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Our business concept focuses on development and marketing of stable fibroblast growth factors (FGFs) for medical, personal care and research use. FGFs are currently being tested therapeutically for use in cancer treatment, regenerative medicine, as well as in cosmetics. The FGF-based therapeutic approaches contribute towards promoting active and healthy ageing, which is a societal challenge common to all European countries. Another important application of FGFs is in the highly attractive cancer stem cell research with the extension to clinical applications. FGFs are being used as an essential reagent ensuring that stem cells are kept in the undifferentiated state. However, FGF instability is one of the major bottlenecks preventing wider use of FGFs. The FGFSTAB project will address this instability by computer-assisted design of multiple stabilizing mutations combined with cutting-edge molecular biology techniques. The expected outcomes of the project will be a universal protein engineering platform for designing stable FGFs and the process for manufacturing of stable FGFs that are not commercially available, even though there is a huge market for them. Added value of our innovation compared to existing solutions will be unprecedented stability, dramatic production cost reductions and the absence of harmful additives. Such FGFs will have much broader applicability than currently used natural molecules. Because of the wide range of products based on FGFs nowadays, we expect that the outcomes of the project will help us to access new high-value markets addressing global societal challenges, such as health care, bio-research, and personal care. All these market segments are characterized by the considerable size, growth and potential impact on people’s everyday lives. The phase 1 of the SME instrument will allow us to carry out well-researched feasibility study which will help us to take our business forward with confidence, and ultimately, increase our bottom line.

Keywords: fibroblast growth factors,therapeutic proteins,regenerative medicine,stem cell research,anti aging,treatment,protein engineering,in silico design for protein stabilization,protein production
Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support (ADVOS-COVID-19)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-10-01
End date: 2023-06-30
Duration (months): 33.0
Total project cost (EUR): 1381605.0
EU funding (EUR): 951946.1
Participants: 1
Project status: SIGNED

ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patient with MOF is being treated with ADVOS in Germany at present with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion (2.3m€ grant). Following the urgent EU call for corona solutions, we apply now for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources as well as accelerated clinical evidence for medical indication guidance. Integrating fluid-based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). This relates especially to the removal of CO2 (by ADVOS) which relieves the lung and reduces the need/invasiveness of ventilation.

Keywords: sars cov 2 infection,covid 19,corona virus,multiple organ failure,critical care,hemodialysis technology,extracorporeal treatment,improvement of survival,health economics